1. 1416PImmunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO). (23rd October 2018) Authors: Ferrara, R; Naigeon, M; Auclin, E; Duchemann, B; Cassard, L; Medhi, J; Boselli, L; Grivel, J; Desnoyer, A; Mezquita, L; Aboubakar, F; Hendriks, L; Planchard, D; Caramella, C; Remon, J; Ngocamus, M; Nicotra, C; Besse, B; Chaput, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1806PDMultiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome. (23rd October 2018) Authors: Cedres Perez, S; Sanso, M; Hernando-Calvo, A; Callejo, A; Pardo Aranda, N; Navarro Mendivil, A; Martinez, A; Remon, J; Miquel, J M; Rodriguez, G; Monton, V; Villacampa, G; Dienstmann, R; Vivancos, A; Felip Font, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 30PClinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients. (16th September 2018) Authors: Remon, J; Mezquita, L; Planchard, D; Jovelet, C; Lacroix, L; Rouleau, E; Howarth, K; Plagnol, V; Morris, C; Green, E; Le Pechoux, C; Caramella, C; Adam, J; Besse, B Journal: Annals of oncology Issue: Volume 29:Number 6(2018)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Are liquid biopsies a surrogate for tissue EGFR testing?. (15th February 2018) Authors: Goldman, J W; Noor, Z S; Remon, J; Besse, B; Rosenfeld, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 1 Page Start: i38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. (3rd September 2019) Authors: Mountzios, G; Remon, J; Novello, S; Blais, N; Califano, R; Cufer, T; Dingemans, A M; Liu, S V; Peled, N; Pennell, N A; Reck, M; Rolfo, C; Tan, D; Vansteenkiste, J; West, H; Besse, B Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1686 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗